A Phase 2 interventional study of Celecoxib and Ketorolac in Pain, Postoperative, sponsored by Michael Ulm, MD. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-07.
Sponsored by Michael Ulm, MD · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing celecoxib in Pain, Postoperative — 2 open to participants now, 2 under way, none of them phase 3. Celecoxib · Pain, Postoperative.
Among the 19 studies testing celecoxib in Pain, Postoperative, this one is the 8th largest by enrollment, is the only one that started in 2013, is one of 5 in phase 2, and was the 7th registered.
5,671 studies on the registry are indexed under Pain, Postoperative; 1,241 are open to participants now.
Browse Pain, Postoperative studies →2 of the 19 studies testing celecoxib in Pain, Postoperative are open now, in 1 country. Recruiting first, the newest first:
Northwell Health · Sites in United States
Women only · Healthy volunteers
NYU Langone Health · Sites in United States
Ages 2–18
By country, each count listing its studies:
Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 677 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 5 · Phase 4 5
First in 2004; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 170 is above the median of 75 across 4,850 interventional studies indexed under Pain, Postoperative.
Median enrollment 132 across the 19 interventional studies. Of the 15 that completed or were terminated, 5 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 19 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Michael Ulm, MD as lead sponsor.
Michael Ulm, MD has 1 study filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
1 of the studies testing celecoxib in Pain, Postoperative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06379425Northwell HealthImpact of Preoperative Opioid-free Multimodal Analgesia on Time to Trial of Void in Ambulatory Urogynecologic Surgeries | 2027-01-01 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing celecoxib in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Randomized control trial between ketorolac versus celecoxib for postoperative pain following hysterectomy.
Purpose:
To determine if Celebrex (Celecoxib) is as effective as Toradol (Ketorolac) at controlling postoperative pain when given in addition to standard postoperative pain control regimens.
Rationale:
Toradol (Ketorolac) is currently used by many surgeons as adjuvant therapy in addition to standard narcotics in managing immediate postoperative pain. Toradol (Ketorolac) is a non-steroidal anti-inflammatory drug that acts as a non-selective cyclooxygenase (COX), inhibiting COX-1 and COX-2 isoforms. (Toradol) Ketorolac has been associated with significant complications including postoperative bleeding and acute renal insufficiency. Celebrex (Celecoxib) is a selective COX-2 inhibitor that has been associated with adverse cardiovascular outcomes in patients with pre-existing cardiac disease but not with postoperative bleeding or renal insufficiency. Celebrex (Celecoxib) has also been shown to control postoperative pain but has never been compared to Toradol (Ketorolac).
Population:
Patients undergoing hysterectomy on the gynecology oncology service.
Design:
Randomized control trial.
Procedures:
All patients will receive a standard postoperative pain regimen with oral Tylenol (Acetaminophen), oral Lortab (Hydrocodone/Acetaminophen) as needed, and IV Dilaudid (Hydromorphone) as needed.
Randomization: Each participant will be assigned a number using a random number generator for assignment to one of the two postoperative pain regimens:
Arm 1:
Patients ages 18-65 will receive IV Toradol (Ketorolac) 30mg q6 hrs after their operation for 48 hrs or until hospital discharge if patients are discharged home in less than 48 hours after their operation.
**Patients over age 65 will receive IV Toradol (Ketorolac) 15mg q6hrs instead of 30mg
Arm 2:
Patients who will receive oral Celebrex (Celecoxib) 400mg 1 hour prior to their procedure then 200mg oral twice daily for a total of seven days. Patients discharged prior to 7 days will be given a prescription for Celebrex (Celecoxib) to complete a total of 7 days.
Following surgery all patients will be given a postoperative questionnaire at the day of surgery, which was returned at the two week postoperative visit, examining time until return to ADLs, days of narcotic use, and number of narcotic pills used.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients receiving scheduled ketorolac postoperatively
Drug: Ketorolac
Patients receiving celebrex preoperative and postoperatively for 7 days
Drug: Celecoxib
Average Inpatient Postoperative Pain Score
Pain measured using the Visual Analog Scale, no pain (0-0.4 cm), mild pain(0.5-4.4 cm), moderate pain (4.5-7.4 cm), and severe pain (7.5-10.0 cm). Subscale scoring was not used in analysis but provided as reference for patient and nursing staff.
Time frame: 48 hrs following surgery
Average Inpatient Hydromorphone Use
Average inpatient hydromorphone use measured in milligrams
Time frame: 48 hrs following surgery
Average Inpatient Ondansetron Use
Average inpatient ondansetron use measured in milligrams
Time frame: 48 hrs following surgery
Total Hospital Stay
Total hospital stay from time fo admission to time of discharge measured in hours
Time frame: Following surgery
Number of Participants With Perioperative Complications
Perioperative Complications measured intraoperatively and postoperatively by type
Time frame: During and after surgery
Return to Activities of Daily Living
Average number of days required for complete return to independent activities of daily living
Time frame: 2 weeks after discharge
Days of Oral Narcotic Use After Discharge
Measured using postoperative questionnaire
Time frame: 2 weeks after discharge
Number of Oral Narcotic Pills Used After Discharge
Number of oral narcotic pills used after discharge until 2 week postoperative visit.
Time frame: 2 weeks after discharge
| Milestone | Ketorolac | Celecoxib |
|---|---|---|
| Started | 88 | 82 |
| Completed | 70 | 68 |
| Not completed | 18 | 14 |
| Withdrew: Physician decision | 18 | 14 |
Pain measured using the Visual Analog Scale, no pain (0-0.4 cm), mild pain(0.5-4.4 cm), moderate pain (4.5-7.4 cm), and severe pain (7.5-10.0 cm). Subscale scoring was not used in analysis but provided as reference for patient and nursing staff.
| units on a scale | Ketorolac | Celecoxib |
|---|---|---|
| Average Inpatient Postoperative Pain Score | 2.7 ± 1.9 | 2.4 ± 1.6 |
Average inpatient hydromorphone use measured in milligrams
| Milligrams | Ketorolac | Celecoxib |
|---|---|---|
| Average Inpatient Hydromorphone Use | 0.7 ± 1.0 | 0.8 ± 1.0 |
Average inpatient ondansetron use measured in milligrams
| Milligrams | Ketorolac | Celecoxib |
|---|---|---|
| Average Inpatient Ondansetron Use | 1.5 ± 1.9 | 1.3 ± 2.2 |
Total hospital stay from time fo admission to time of discharge measured in hours
| Hours | Ketorolac | Celecoxib |
|---|---|---|
| Total Hospital Stay | 11.6 ± 8.1 | 11.9 ± 7.6 |
Perioperative Complications measured intraoperatively and postoperatively by type
| Patients | Ketorolac | Celecoxib |
|---|---|---|
| Number of Participants With Perioperative Complications | 5 | 6 |
Average number of days required for complete return to independent activities of daily living
| Days | Ketorolac | Celecoxib |
|---|---|---|
| Return to Activities of Daily Living | 2.4 ± 0.8 | 2.2 ± 0.9 |
Measured using postoperative questionnaire
| Days | Ketorolac | Celecoxib |
|---|---|---|
| Days of Oral Narcotic Use After Discharge | 5.7 ± 2.8 | 3.8 ± 2.6 |
Number of oral narcotic pills used after discharge until 2 week postoperative visit.
| Pills | Ketorolac | Celecoxib |
|---|---|---|
| Number of Oral Narcotic Pills Used After Discharge | 8.1 ± 4.0 | 6.0 ± 3.6 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ketorolac | — | 0/70 (0%) | 1/70 (1.4%) |
| Celecoxib | — | 0/68 (0%) | 2/68 (2.9%) |
| Event | Ketorolac | Celecoxib |
|---|---|---|
| Intraoperative HemorrhageBlood and lymphatic system disorders | 0/70 | 2/68 |
| Acute Kidney InjuryRenal and urinary disorders | 1/70 | 0/68 |
| Age, Continuous(years) | Ketorolac | Celecoxib | Total |
|---|---|---|---|
| Mean | 56.3 ± 11.3 | 55.1 ± 14.4 | 55.7 ± 12.0 |
| Sex: Female, Male(Participants) | Ketorolac | Celecoxib | Total |
|---|---|---|---|
| Female | 70 | 68 | 138 |
| Male | 0 | 0 | 0 |
| Body Mass Index(Kg/m^2) | Ketorolac | Celecoxib | Total |
|---|---|---|---|
| Mean | 31.8 ± 8.6 | 31.7 ± 8.1 | 31.7 ± 8.3 |
| Surgical Pathology(Participants) | Ketorolac | Celecoxib | Total |
|---|---|---|---|
| Benign | 48 | 53 | 101 |
| Malignant | 22 | 15 | 37 |
| Procedure(Participants) | Ketorolac | Celecoxib | Total |
|---|---|---|---|
| Robotic Assisted Hysterectomy, +/- BSO, Cysto | 48 | 53 | 101 |
| Robotic Assisted Hysterectomy, +/- BSO, LND, Cysto | 22 | 15 | 37 |
| Operative Time(Minutes) | Ketorolac | Celecoxib | Total |
|---|---|---|---|
| Mean | 105 ± 32 | 104 ± 34 | 104 ± 33 |
| Trochar Sites(Trochars) | Ketorolac | Celecoxib | Total |
|---|---|---|---|
| Mean | 4.3 ± 0.5 | 4.2 ± 0.4 | 4.2 ± 0.5 |
| Preoperative Diagnosis(Participants) | Ketorolac | Celecoxib | Total |
|---|---|---|---|
| Malignancy | 21 | 15 | 36 |
| Premalignancy | 14 | 15 | 29 |
| Leiomyoma | 8 | 4 | 12 |
| Pelvic Pain | 11 | 8 | 19 |
| Abnormal Uterine Bleeding | 3 | 8 | 11 |
| Adnexal Mass | 10 | 14 | 24 |
| Genetic Predisposition to Malignancy | 3 | 4 | 7 |
Ran from Sep 2013 to primary completion in Jun 2016, 33 months.
Results were first posted in Jun 2018, 1 year 11 months after primary completion.
Of 90 non-industry phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 33 months is above that.
Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Celecoxib